Dr Sunil Verma Discusses Adding Durvalumab to Cholangiocarcioma Chemotherapy Combination
Hayden E. Klein
Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, discusses the addition of durvalumab to a chemotherapy regimen of gemcitabine and cisplatin for biliary duct cancer.
Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, discusses the addition of durvalumab to a chemotherapy regimen of gemcitabine and cisplatin for
TOPAZ-1 results were i
Transcript
Can you discuss the mechanism of action of adding durvalumab to gemcitabine/cisplatin chemotherapy in biliary duct cancer?
What we have learned through many other tumor types—including lung cancer, breast cancer, and other emerging tumor types—in certain tumors, single-agent monotherapy IOs [immunotherapies] can be very effective. In melanoma, non–small cell lung cancer with high PD-L1 expression, single-agent monotherapy with IO was very effective.
But in many other tumors, which tend to be much more on the colder range, where the immune system is maybe not as activated, you need chemotherapy to trigger the immune cascade. We identified that biliary tract cancer was likely one of the tumors where we needed a chemotherapy foundation combination to trigger the immune cascade, which would then be enhanced with the combination of checkpoint inhibitors. So in this study, we had a chemotherapy foundation with cisplatin/gemcitabine, and then IO with durvalumab was added on top.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025